New hope for hard-to-treat bile duct cancer: combo therapy shows promise
NCT ID NCT05994001
First seen Feb 20, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has not responded to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or slow the disease. About 78 adults with a specific protein (Claudin 18.2) on their cancer cells will take part. This is not a cure, but aims to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.